ASRT Key Statistics, Chart & Performance
The current stock price of ASRT is 0.735 USD. In the past month the price decreased by -2.26%. In the past year, price decreased by -26.5%.
ASRT Latest News, Press Relases and Analysis
ASRT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.91 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.93 | 498.33B | ||
| MRK | MERCK & CO. INC. | 11.9 | 261.84B | ||
| PFE | PFIZER INC | 8.04 | 146.35B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.14B | ||
| ZTS | ZOETIS INC | 20.22 | 56.49B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.74 | 23.34B | ||
| VTRS | VIATRIS INC | 4.59 | 12.31B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.24 | 11.56B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.23 | 8.35B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.56B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.80B |
Related stock screener links
About ASRT
Company Profile
Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The company is headquartered in Lake Forest, Illinois and currently employs 58 full-time employees. The firm has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Company Info
ASSERTIO HOLDINGS INC
100 S. Saunders Road, Suite 300
Lake Forest ILLINOIS 60045 US
CEO: Daniel A. Peisert
Employees: 58
Phone: 12244197106
ASSERTIO HOLDINGS INC / ASRT FAQ
Can you describe the business of ASSERTIO HOLDINGS INC?
Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The company is headquartered in Lake Forest, Illinois and currently employs 58 full-time employees. The firm has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Can you provide the latest stock price for ASSERTIO HOLDINGS INC?
The current stock price of ASRT is 0.735 USD. The price increased by 1.65% in the last trading session.
Does ASSERTIO HOLDINGS INC pay dividends?
ASRT does not pay a dividend.
How is the ChartMill rating for ASSERTIO HOLDINGS INC?
ASRT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of ASSERTIO HOLDINGS INC (ASRT)?
ASSERTIO HOLDINGS INC (ASRT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.2).
Would investing in ASSERTIO HOLDINGS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ASRT.
Is ASSERTIO HOLDINGS INC (ASRT) expected to grow?
The Revenue of ASSERTIO HOLDINGS INC (ASRT) is expected to decline by -8.53% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ASRT Technical Analysis
ASRT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ASRT. While ASRT seems to be doing ok healthwise, there are quite some concerns on its profitability.
ASRT Financial Highlights
Over the last trailing twelve months ASRT reported a non-GAAP Earnings per Share(EPS) of -0.2. The EPS increased by 72.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.9% | ||
| ROE | -26.89% | ||
| Debt/Equity | 0.37 |
ASRT Forecast & Estimates
10 analysts have analysed ASRT and the average price target is 2.72 USD. This implies a price increase of 269.49% is expected in the next year compared to the current price of 0.735.
For the next year, analysts expect an EPS growth of -105.11% and a revenue growth -8.53% for ASRT